Solid Biosciences Inc. Common Stock (SLDB) is a publicly traded Healthcare sector company. As of May 20, 2026, SLDB trades at $6.47 with a market cap of $640.91M and a P/E ratio of -3.19. SLDB moved +6.58% today. Year to date, SLDB is +21.39%; over the trailing twelve months it is +119.32%. Its 52-week range spans $2.41 to $8.87. Analyst consensus is strong buy with an average price target of $17.33. Rallies surfaces SLDB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Solid Biosciences Doses First Phase 3 Duchenne Participant, Holds $380.7M Cash Runway: Solid Biosciences held $380.7 million in cash and equivalents, extending its runway into H1 2028, and dosed the first participant in its Phase 3 IMPACT DUCHENNE trial for SGT-003, which secured EMA positive pediatric investigation plan opinion and European Commission orphan designation. The company dosed a second Friedreich’s ataxia Phase 1b participant.
| Metric | Value |
|---|---|
| Price | $6.47 |
| Market Cap | $640.91M |
| P/E Ratio | -3.19 |
| EPS | $-1.99 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.87 |
| 52-Week Low | $2.41 |
| Volume | 974.73K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-174.32M |
| Gross Margin | 0.00% |
11 analysts cover SLDB: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $17.33.